ArticleWorld journal of pediatric surgery2025
Wound dehiscence rates decreased in reconstructive surgery of anorectal malformations after introduction of a standardized postoperative treatment program.
Article in World journal of pediatric surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Wound dehiscence is a known complication after anorectal malformations (ARMs) surgery. The aim was to evaluate if a standardized post-posterior sagittal anorectoplasty (PSARP) treatment program decreased wound dehiscence rates. Methods: Wound dehiscence rates within 30 days post-PSARP were compared in a case-control single-center study between patients with a standardized post-PSARP treatment 2017-2023, and a cohort with a non-standardized management 2001-2016. The standardized post-PSARP program comprised a minimum of 3 days of: intravenous antibiotics imipenem+cilastatin (with optional subsequent oral amoxicillin+clavulanic acid+metronidazole), fasting after primary PSARP (no stoma), urinary catheter and regular wound cleansing. Results: A total of 149 patients (61% males) with various ARM subtypes were included of which 51% were reconstructed with stomas. Overall, wound dehiscence developed in 8 of 59 patients (14%) in the standardized post-PSARP program group versus 28 of 90 patients (31%) in the control group ( Conclusion: Wound dehiscence rates may be reduced using a standardized post-PSARP treatment program.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.